Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 22,362 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 22,362 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $6.62, for a total value of $148,036.44. Following the sale, the chief executive officer owned 6,025,840 shares in the company, valued at approximately $39,891,060.80. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $88,787.60.
• On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total transaction of $188,395.08.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $6.38 on Thursday. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $7.78 and its 200 day moving average price is $5.33. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $9.24. The stock has a market cap of $337.31 million, a price-to-earnings ratio of -7.09 and a beta of 2.42.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10. The company had revenue of $19.91 million during the quarter, compared to analysts’ expectations of $17.74 million. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. As a group, research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after acquiring an additional 3,785 shares during the last quarter. CWM LLC grew its holdings in Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after purchasing an additional 3,137 shares during the period. Tower Research Capital LLC TRC increased its position in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. Bank of Montreal Can purchased a new position in Sight Sciences during the second quarter worth approximately $49,000. Finally, R Squared Ltd acquired a new position in shares of Sight Sciences in the 3rd quarter valued at $64,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

SGHT has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th. Citigroup lifted their price objective on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Raymond James Financial set a $9.00 target price on shares of Sight Sciences in a research note on Monday, January 5th. Lake Street Capital raised their price target on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Finally, Piper Sandler set a $9.00 price target on shares of Sight Sciences in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.30.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.